Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02238210
Other study ID # 244.2503
Secondary ID
Status Completed
Phase Phase 4
First received September 11, 2014
Last updated September 11, 2014
Start date December 2002

Study information

Verified date September 2014
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Study to determine the safety of Atrovent Nasal Spray 0.06% in pediatric patients (ages 2-5 years) with symptoms of rhinorrhea associated with a naturally occurring common cold or from symptoms of rhinorrhea associated with allergies


Recruitment information / eligibility

Status Completed
Enrollment 230
Est. completion date
Est. primary completion date May 2003
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 5 Years
Eligibility Inclusion Criteria for patients with common cold

- Male or female at least 2 but not older than 5 years of age at screening

- Have a diagnosis of a common cold defined as presence of acute onset of rhinorrhea (within 48 hours of screening visit) and at least 1 of the following:

- Presence of swollen nasal membranes characteristic of a common cold on examination at screening

- Presence of fever up to 102°F (oral or equivalent) within 48 hours of visit (may be taken at home/away from the clinic) or at time of screening

- Capability of parent/legal guardian to read and understand the informed consent, record trial diary information, administer trial drug and read and understand trial assessment questionnaire

Inclusion Criteria for patients with allergies

- Male or female at least 2 but not older than 5 year of age

- Have a diagnosis of seasonal or perennial allergic rhinitis defined as having both of the following:

- Positive skin or Radioallergosorbent test (RAST) test to a relevant allergen within 12 months of screening or at the screening visit. For the purpose of this trial a positive skin test is defined as wheal diameter that is at least 3 mm greater than the negative control

- Positive prior history for atopy with nasal symptoms associated with expose to allergens

- Symptoms associated with rhinorrhea for at least 48 hours prior to the screening visit

- Capability of parent/legal guardian to read and understand the informed consent, record trial diary information, administer trial drug and read and understand trial assessment questionnaire

General Exclusion Criteria for both common cold and allergy

- Significant cardiovascular, renal, hepatic, endocrine, metabolic, neurologic or other systemic disease. A significant disease was defined as one which, in the opinion of the Investigator, either put the patient at risk because of participation in the trial or influenced the results of the trial or the patient's ability to participate in the trial

- Presence of rales or rhonchi suggestive of a lower respiratory tract infection

- An oral (or equivalent) temperature higher than 102°F

- Presence of otitis media

- Be initiating or advancing immunotherapy regimen during the course of this trial. Patients receiving a maintenance dose of immunotherapy are eligible

- Known intolerance to anticholinergics of hypersensitivity to benzalkonium chloride

- Excluded medications prior to Visit 1 and during the trial included:

1. 24 hours before

- Over-the-counter decongestants or nasal/ocular cromolyn

2. 3 days before:

- Anticholinergics

- Over-the-counter antihistamines

- sympathomimetic decongestants

3. 5 days before:

- Fexofenadine

- Loratadine

4. 7 days before:

- Cetirizine

- antihistamines such as Atarax® or doxepin hydrochloride

- Antidepressants

5. 14 days before:

- Intranasal steroids

6. 28 days before:

- Steroids (oral and injectable)

- Leukotriene modifiers (e.g. Accolate®, Singulair®)

- Other investigational drugs

- Participation in any trial with an investigational drug within 30 days of the screening visit

- Nasal obstruction greater than 50% that would prevent deposition of trial drug

- The parent/legal guardian has a disability or lives in a geographical location that could impair compliance with the protocol or visits to the trial center

Exclusion criteria for patients with a common cold

- History or perennial allergic rhinitis or seasonal allergic rhinitis (SAR) with allergen in season

- Positive Streptococcus test

Exclusion criteria for patients with allergies

- Patients with active infectious rhinitis (common cold) as determined by history and physical

- Patients with upper or lower respiratory infection at screening

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Atrovent®


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Boehringer Ingelheim

Outcome

Type Measure Description Time frame Safety issue
Primary Patient's parent/legal guardian global assessment - common cold group Day 4 No
Primary Number of patients with adverse events up to 21 days No
Primary Patient's parent/legal guardian global assessment - allergy group Day 14 No
Secondary Patient's parent/legal guardian daily assessment of rhinorrhea (runny nose) rated on 5-point scale - common cold group daily assessment by e-diary Day 4 No
Secondary Patient's parent/legal guardian daily assessment of nasal congestion (stuffy nose) rated on 5-point scale - common cold group daily assessment by e-diary Day 4 No
Secondary Patient's parent/legal guardian daily assessment of sneezing rated on 5-point scale - common cold group daily assessment by e-diary Day 4 No
Secondary Number of patients with clinically findings in nasal and otoscopic examination - common cold group up to day 4 No
Secondary Patient's parent/legal guardian daily assessment of rhinorrhea (runny nose) rated on 5-point scale - allergy group daily assessment by e-diary Day 14 No
Secondary Patient's parent/legal guardian daily assessment of nasal congestion (stuffy nose) rated on 5-point scale - allergy group daily assessment by e-diary Day 14 No
Secondary Patient's parent/legal guardian daily assessment of sneezing rated on 5-point scale - allergy group daily assessment by e-diary Day 14 No
Secondary Number of patients with clinically findings in nasal and otoscopic examination - allergy group up to day 14 No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02735070 - Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold Phase 3
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Not yet recruiting NCT05118672 - Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment Phase 3
Recruiting NCT06158659 - Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula N/A
Active, not recruiting NCT05190432 - Taxifolin/Ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr) N/A
Not yet recruiting NCT03089138 - Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome Phase 2
Completed NCT00289237 - Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease N/A
Recruiting NCT05728918 - Effectiveness of Antrodia Cinnamomea Mycelia on Improving Immune Response in Subhealth People N/A
Recruiting NCT02183779 - PORH and Response to Cold in Raynaud's Phenomenon. N/A
Completed NCT05920915 - The Effect of the Cold Application on Venous Cannulation Pain N/A
Recruiting NCT05454826 - Investigation of the Effect of Cold Application in Migraine N/A
Recruiting NCT04277494 - The Acute Effect of Cold Spray Application on the Mechanical Properties of the Quadriceps Muscle in Athletes N/A
Completed NCT01533220 - Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal Phase 3
Not yet recruiting NCT04277481 - The Acute Effect of Cold Pack Therapy Applied on Healthy People for Different Periods
Completed NCT03769012 - Ability of Beta-glucan Supplementation to Augment Immune Function N/A
Suspended NCT02904304 - Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu Phase 3
Recruiting NCT05435144 - Elderberry for Immune Support N/A
Completed NCT02847663 - The Effect of Whole Body Cryotherapy on Recovery and Performance: a Randomized Controlled Trial N/A
Recruiting NCT02457533 - Case Management - Active Telephone Support to Patients With COLD N/A
Not yet recruiting NCT05317156 - The Effect of Cold Vapor on Intubation-Related Symptoms and Comfort in the Early Postoperative Period N/A

External Links